Characteristic | Referred1 | Discussed2 | Consultation3 |
|---|
n/N (%) | Adjusted # RR (95% CI) | n/N (%) | Adjusted # RR (95% CI) | n/N (%) | Adjusted # RR (95% CI) |
|---|
All patients: | 325/1071 (30%) | | 354/1071 (33%) | | 278/1071 (26%) | |
Study phase |
Control | 154/505 (30%) | ref. | 88/505 (17%) | ref. | 138/505 (27%) | ref. |
Transition | 41/159 (26%) | 0.99 (0.68, 1.46) | 26/159 (16%) | 1.52 (0.90, 2.58) | 33/159 (21%) | 0.99 (0.72, 1.35) |
Intervention | 130/407 (32%) | 1.06 (0.74, 1.51) | 240/407 (59%) | 4.32 (2.40, 7.75) | 107/407 (26%) | 1.05 (0.74, 1.51) |
p value | | 0.879 | | < 0.001 | | 0.896 |
- 1Patient referred within 4 months after prostatectomy to either a radiation oncologist or to the RAVES trial
- 2Patient discussed at MDT meeting within 4 months after prostatectomy
- 3Patient had consultation with radiation oncologist within 6 months after RP following referral within 4 months after RP
- #Adjusted for age at prostatectomy (40–59, 60–69, 70+), extracapsular extension (no, yes, unsure), positive surgical margin (no, yes, unsure), seminal vesicle invasion (no, yes, unsure), regional lymph node involvement (no, yes, unsure), post-operative Gleason score (6–7, 8, 9–10, unsure), maximum PSA level within 4 months after RP (< 0.1 ng/ml, ≥ 0.1 ng/ml, no PSA test recorded), number of co-morbidities (0, 1, 2, 3+), site (1 through 9), calendar time period of surgery (four time periods) and urologist as the GEE clustering variable
- 19 patients with “unsure” extracapsular extension, positive surgical margin and/or seminal vesicle invasion were excluded from regression analysis because low numbers in those groups prevented model convergence
